GUTS
Fractyl Health, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$0.70
+1.35%Sep 3, 2026, 14:40 UTC
A class action lawsuit was filed against Fractyl Health, Inc. on behalf of investors who purchased securities between January 13, 2025 and January 29, 2026.
Source:Sep 1, 2026, 16:00 UTC
Glancy Prongay Wolke & Rotter LLP announced a securities fraud lawsuit on behalf of Fractyl Health, Inc. shareholders who suffered losses, related to the company's disclosure of REMAIN-1 Midpoint Cohort data on January 29, 2026.
Source:Aug 14, 2026, 09:04 UTC
Fractyl Health launched a clinical trial for its Rejuva gene therapy, a one-time treatment for obesity and type 2 diabetes.
Source:Aug 10, 2026, 23:05 UTC
Fractyl Health announced that its Revita endoscopic procedure demonstrated durable weight-maintenance results one year after patients discontinued GLP-1 therapy.
Source:Jul 15, 2026, 13:03 UTC
Fractyl Health reported one-year data from the REMAIN-1 study showing its Revita procedure helped patients maintain weight loss after stopping GLP-1 therapy.
Source: